Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations

ABSTRACT Introduction: Retroperitoneal lymph node dissection (RPLND) is indicated for testicular cancer patients with residual masses post-chemotherapy or stage I-II non-seminomatous germ cell tumors (NSGCT) (1, 2). Open RPLND remains the standard but carries significant morbidity. The laparoscopic...

Full description

Saved in:
Bibliographic Details
Main Authors: Sisto Perdonà, Alessandro Izzo, Roberto Contieri, Francesco Passaro, Savio Domenico Pandolfo, Roberto Corrado, Giovanna Canfora, Rocco Damiano, Riccardo Autorino, Gianluca Spena
Format: Article
Language:English
Published: Sociedade Brasileira de Urologia 2025-08-01
Series:International Brazilian Journal of Urology
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382025000500800&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849233801190834176
author Sisto Perdonà
Alessandro Izzo
Roberto Contieri
Francesco Passaro
Savio Domenico Pandolfo
Roberto Corrado
Giovanna Canfora
Rocco Damiano
Riccardo Autorino
Gianluca Spena
author_facet Sisto Perdonà
Alessandro Izzo
Roberto Contieri
Francesco Passaro
Savio Domenico Pandolfo
Roberto Corrado
Giovanna Canfora
Rocco Damiano
Riccardo Autorino
Gianluca Spena
author_sort Sisto Perdonà
collection DOAJ
description ABSTRACT Introduction: Retroperitoneal lymph node dissection (RPLND) is indicated for testicular cancer patients with residual masses post-chemotherapy or stage I-II non-seminomatous germ cell tumors (NSGCT) (1, 2). Open RPLND remains the standard but carries significant morbidity. The laparoscopic approach, while minimally invasive, presents notable technical challenges (3). Robotic-assisted RPLND (rRPLND) offers a minimally invasive alternative with comparable oncological outcomes (4, 5). The Da Vinci Single Port (SP) system presents new possibilities for reducing surgical morbidity (6, 7). Methods: We report a case of SP-rRPLND using a unilateral modified template and a lower anterior access (LAA) in a 41-year-old man with NSGCT (pT2, UICC Stage IB) who underwent left orchiectomy, followed by adjuvant chemotherapy. A CT scan revealed a 3.5 cm residual retroperitoneal mass in the left hilar region. The surgical procedure, performed with the Da Vinci SP system, involved a 2.5 cm McBurney incision for retroperitoneal access. Instrument configuration followed a "Camera below" setting. The unilateral left-sided modified template guided dissection from the aortic bifurcation to the renal hilum, preserving vascular structures. A 3,5 cm residual mass and para-aortic nodes were excised with the help of flexible Greena® applicator for clips. Results: Anesthetic management prioritized opioid-sparing techniques to enhance recovery. The patient received regional anesthesia, multimodal analgesia, and had an NRS pain score of 0 at discharge. The console time was 79 minutes, with minimal blood loss and no complications. The patient resumed oral intake on postoperative day 1 and was discharged on day 2. Postoperative recovery was uneventful, with no complications or need for conversion to open or laparoscopic surgery. Final histopathological examination revealed a germ cell tumor with features suggestive of immature teratoma, along with over 10 lymph nodes showing sinus histiocytosis. At six months post-RPLND, the patient remains disease-free, with a good general condition and no new symptoms. Tumor markers (AFP, β-hCG, LDH) are within normal limits, and CT imaging shows no evidence of recurrence or residual retroperitoneal masses. Renal function and hormonal profile are stable. Given prior chemotherapy exposure, cardiovascular monitoring is advised. Follow-up will continue with clinical exams and tumor markers every 3-4 months, with the next CT scan planned at 12 months, unless symptoms warrant earlier imaging. Conclusions: As far as we know this is the first reported case of SP-rRPLND in Europe. The LAA provides safe access while minimizing morbidity, potentially improving recovery (8). A unilateral approach, avoiding transperitoneal access, may further reduce morbidity (9). Future studies should validate long-term oncological outcomes and compare SP-rRPLND with multiport and open approaches. SP-rRPLND represents a promising advancement in minimally invasive testicular cancer surgery.
format Article
id doaj-art-b011a11d4bd84569b2c9bfc0eb275107
institution Kabale University
issn 1677-6119
language English
publishDate 2025-08-01
publisher Sociedade Brasileira de Urologia
record_format Article
series International Brazilian Journal of Urology
spelling doaj-art-b011a11d4bd84569b2c9bfc0eb2751072025-08-20T04:03:25ZengSociedade Brasileira de UrologiaInternational Brazilian Journal of Urology1677-61192025-08-0151510.1590/s1677-5538.ibju.2025.0091Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical ConsiderationsSisto PerdonàAlessandro IzzoRoberto ContieriFrancesco PassaroSavio Domenico PandolfoRoberto CorradoGiovanna CanforaRocco DamianoRiccardo AutorinoGianluca Spenahttps://orcid.org/0000-0002-6714-9315ABSTRACT Introduction: Retroperitoneal lymph node dissection (RPLND) is indicated for testicular cancer patients with residual masses post-chemotherapy or stage I-II non-seminomatous germ cell tumors (NSGCT) (1, 2). Open RPLND remains the standard but carries significant morbidity. The laparoscopic approach, while minimally invasive, presents notable technical challenges (3). Robotic-assisted RPLND (rRPLND) offers a minimally invasive alternative with comparable oncological outcomes (4, 5). The Da Vinci Single Port (SP) system presents new possibilities for reducing surgical morbidity (6, 7). Methods: We report a case of SP-rRPLND using a unilateral modified template and a lower anterior access (LAA) in a 41-year-old man with NSGCT (pT2, UICC Stage IB) who underwent left orchiectomy, followed by adjuvant chemotherapy. A CT scan revealed a 3.5 cm residual retroperitoneal mass in the left hilar region. The surgical procedure, performed with the Da Vinci SP system, involved a 2.5 cm McBurney incision for retroperitoneal access. Instrument configuration followed a "Camera below" setting. The unilateral left-sided modified template guided dissection from the aortic bifurcation to the renal hilum, preserving vascular structures. A 3,5 cm residual mass and para-aortic nodes were excised with the help of flexible Greena® applicator for clips. Results: Anesthetic management prioritized opioid-sparing techniques to enhance recovery. The patient received regional anesthesia, multimodal analgesia, and had an NRS pain score of 0 at discharge. The console time was 79 minutes, with minimal blood loss and no complications. The patient resumed oral intake on postoperative day 1 and was discharged on day 2. Postoperative recovery was uneventful, with no complications or need for conversion to open or laparoscopic surgery. Final histopathological examination revealed a germ cell tumor with features suggestive of immature teratoma, along with over 10 lymph nodes showing sinus histiocytosis. At six months post-RPLND, the patient remains disease-free, with a good general condition and no new symptoms. Tumor markers (AFP, β-hCG, LDH) are within normal limits, and CT imaging shows no evidence of recurrence or residual retroperitoneal masses. Renal function and hormonal profile are stable. Given prior chemotherapy exposure, cardiovascular monitoring is advised. Follow-up will continue with clinical exams and tumor markers every 3-4 months, with the next CT scan planned at 12 months, unless symptoms warrant earlier imaging. Conclusions: As far as we know this is the first reported case of SP-rRPLND in Europe. The LAA provides safe access while minimizing morbidity, potentially improving recovery (8). A unilateral approach, avoiding transperitoneal access, may further reduce morbidity (9). Future studies should validate long-term oncological outcomes and compare SP-rRPLND with multiport and open approaches. SP-rRPLND represents a promising advancement in minimally invasive testicular cancer surgery.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382025000500800&lng=en&tlng=en
spellingShingle Sisto Perdonà
Alessandro Izzo
Roberto Contieri
Francesco Passaro
Savio Domenico Pandolfo
Roberto Corrado
Giovanna Canfora
Rocco Damiano
Riccardo Autorino
Gianluca Spena
Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations
International Brazilian Journal of Urology
title Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations
title_full Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations
title_fullStr Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations
title_full_unstemmed Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations
title_short Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations
title_sort single port robot assisted post chemotherapy unilateral retroperitoneal lymph node dissection feasibility and surgical considerations
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382025000500800&lng=en&tlng=en
work_keys_str_mv AT sistoperdona singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT alessandroizzo singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT robertocontieri singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT francescopassaro singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT saviodomenicopandolfo singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT robertocorrado singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT giovannacanfora singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT roccodamiano singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT riccardoautorino singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations
AT gianlucaspena singleportrobotassistedpostchemotherapyunilateralretroperitoneallymphnodedissectionfeasibilityandsurgicalconsiderations